【摘要】 目的检测膀胱移行细胞癌(BTCC)和正常膀胱组织中肿瘤坏死因子相关凋亡诱导配体(TRAIL)的表达,探讨TRAIL表达与BTCC预后的关系。方法免疫组化Elivision法检测76例BTCC和15例正常膀胱组织病理标本中TRAIL的表达;结合临床病理学资料分析其之间的相关性。结果76例BTCC病理标本中有45例(59.21%)TRAIL阴性表达,G2、G3组的TRAIL阴性表达率(68.63%)明显高于G1组(40.00%,P<0.05);肿瘤多发组中TRAIL阴性表达率(75.86%)明显高于单发组(48.94%,P<0.05)。log-rank test分析TRAIL表达阴性组与阳性组间无复发生存率有统计学意义(P<0.05),TRAIL阴性表达组的无复发生存时间(33.65月)明显低于阳性表达组(46.49月)。结论TRAIL在BTCC中表达下调,且与BTCC数目、分级、复发相关,可作为判断BTCC预后的参考指标。更多还原

【Abstract】 Objective To determine expression of tumor necrosis factor-related apoptosis-inducing ligand(TRAIL) in bladder transitional cell carcinoma(BTCC) and normal bladder tissues and to explore the correlation among TRAIL and clinico-pathological parameters and prognosis of BTCC.Methods TRAIL protein expression was determined by immunohistochemistry assay(Elivision).Results TRAIL negative expression was shown in 45(59.21%) of the 76 cases of BTCC,and it was higher in poorly differentiated(G2,G3) tumors than in well differentiated (G1) tumors(68.63% vs 40.00%,P<0.05),and also it was significantly higher in multiple tumors than in single tumors(75.86 % vs 48.94%,P<0.05).Survival curves determined by the Kaplan-Meier method and log-rank test analysis demonstrated that recurrence free survival rates in the group of negative expression of TRAIL were lower than those in the group of positive expression(33.65 months vs 46.49 months,P<0.05).Conclusion Expression of TRAIL has a negative correlation with different tumor numbers,grades and recurrence of BTCC;therefore,it can be used as a promising marker for prognosis.更多还原